KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Non-cash Items (2017 - 2018)

Alnylam Pharmaceuticals (ALNY) has disclosed Non-cash Items for 7 consecutive years, with $149.5 million as the latest value for Q4 2018.

  • For the quarter ending Q4 2018, Non-cash Items fell 75.47% year-over-year to $149.5 million, compared with a TTM value of $149.5 million through Dec 2018, down 75.47%, and an annual FY2018 reading of $149.5 million, down 75.47% over the prior year.
  • Non-cash Items was $149.5 million for Q4 2018 at Alnylam Pharmaceuticals, down from $609.6 million in the prior quarter.
  • Across five years, Non-cash Items topped out at $609.6 million in Q4 2017 and bottomed at $4.7 million in Q4 2014.
  • Average Non-cash Items over 3 years is $254.6 million, with a median of $149.5 million recorded in 2018.
  • The sharpest move saw Non-cash Items decreased 11.05% in 2014, then tumbled 75.47% in 2018.
  • Year by year, Non-cash Items stood at $4.7 million in 2014, then skyrocketed by 12772.04% to $609.6 million in 2017, then crashed by 75.47% to $149.5 million in 2018.
  • Business Quant data shows Non-cash Items for ALNY at $149.5 million in Q4 2018, $609.6 million in Q4 2017, and $4.7 million in Q4 2014.